ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells.

Science Signaling
P. Cruz-GordilloMichael J Lee

Abstract

Targeted therapeutics for cancer generally exploit "oncogene addiction," a phenomenon in which the growth and survival of tumor cells depend on the activity of a particular protein. However, the efficacy of oncogene-targeted therapies varies substantially. For instance, targeting epidermal growth factor receptor (EGFR) signaling is effective in some non-small cell lung cancer (NSCLC) but not in triple-negative breast cancer (TNBC), although these cancers show a similar degree of increase in EGFR activity. Using a genome-wide CRISPR-Cas9 genetic knockout screen, we found that the Elongator (ELP) complex mediates insensitivity to the EGFR inhibitor erlotinib in TNBC cells by promoting the synthesis of the antiapoptotic protein Mcl-1. Depleting ELP proteins promoted apoptotic cell death in an EGFR inhibition-dependent manner. Pharmacological inhibition of Mcl-1 synergized with EGFR inhibition in a panel of genetically diverse TNBC cells. The findings indicate that TNBC "addiction" to EGFR signaling is masked by the ELP complex and that resistance to EGFR inhibitors in TNBC might be overcome by cotargeting Mcl-1.

References

Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K M KozopasR W Craig
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jae-Hyun KimDanny Reinberg
Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Dec 15, 2007·Genes & Development·Sreenath V Sharma, Jeffrey Settleman
Apr 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Monique DewezDamien Hermand
Dec 19, 2008·Proceedings of the National Academy of Sciences of the United States of America·Biao LuoDavid E Root
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B CorkeryN O'Donovan
Mar 25, 2011·Science Translational Medicine·Lecia V SequistJeffrey A Engelman
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa A CareyEric P Winer
Dec 18, 2013·Science·Ophir ShalemFeng Zhang
Jan 22, 2015·RNA Biology·Tony KarlsbornAnders S Byström
Feb 15, 2015·EMBO Reports·Raymond PagliariniWilliam R Sellers
Jul 16, 2015·Cancer Biology & Medicine·Hanan Ahmed Wahba, Hend Ahmed El-Hadaad
Oct 28, 2016·Nature·András KotschyOlivier Geneste
Jun 12, 2017·Cell Systems·Giovanni C ForcinaScott J Dixon
Nov 2, 2017·Cell Reports·Paul SavageJiannis Ragoussis
Jul 20, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seiji AraiSen Chen
Oct 17, 2018·Nature Microbiology·D Russ, R Kishony
Feb 25, 2019·Cell Systems·Christian T MeyerVito Quaranta
Aug 24, 2019·Genome Medicine·Medina ColicTraver Hart
Mar 3, 2020·Trends in Pharmacological Sciences·Christian T MeyerVito Quaranta
Apr 7, 2020·Nature Chemical Biology·Ryan RichardsMichael J Lee

❮ Previous
Next ❯

Citations

Jan 10, 2021·Pharmacology & Therapeutics·Juntao LiErxi Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.